### **Deborah Kovacs**

From: Linda Ayers <layers@aad.org>
Sent: Monday, April 13, 2020 2:20 PM
To: misha.rosenbach@uphs.upenn.edu

**Cc:** Deborah Kovacs

**Subject:** AAD Announces COVID-19 Data Registry

## Good afternoon,

On behalf of George J. Hruza, MD, MBA, Chair, AAD Ad Hoc Task Force on COVID-19, we want to share with you the announcement of a COVID-19 dermatology registry, which aims to understand dermatologic manifestations of coronavirus.

While you may have received this announcement as a member of the Academy, we wanted to share it with you in your role as President of the Medical Dermatology Society and encourage you to share it with your members.

The registry, which you may access now on the AAD website at <a href="https://www.aad.org/covidregistry">www.aad.org/covidregistry</a>, is gathering information from all health care providers taking care of:

- COVID-19 patients who develop dermatologic manifestations, or
- Dermatology patients with an existing condition who then develop COVID-19.

It is important to note that a COVID-19 patient does **not** have to have a positive confirmed test to be entered into the registry, as entrants will be able to specify if the case was based on clinical suspicion or on a confirmed test. Also, physicians from any specialty may enter the registry, and we are inviting international physicians to participate as well.

Please share this site with your members and colleagues and encourage them to report any cases of COVID-19 related dermatoses. The form takes only 5 minutes to complete! Additional information about the process is available on the website.

We hope you will join us in this important initiative. Thank you.

# Linda A. Ayers

Associate Director, Constituent Relations and Strategic Planning American Academy of Dermatology 9500 W Bryn Mawr Avenue Suite 500 Rosemont, IL 60018

Phone: 847-240-1251 Email: layers@aad.org

This email may contain privileged or confidential information and is for the sole use of the intended recipient. Any unauthorized use or disclosure of the communication is prohibited. If you believe you have received this email in error, please notify the sender immediately.

From: NewsLetter < newsletter@aad.org> Sent: Wednesday, April 8, 2020 4:31 PM

#### View this email in your browser





# American Medical Association (AMA) letter addresses immediate physician relief

The Academy joined an AMA sign-on letter urging the Department of Health and Human Services (HHS) to provide one month of revenue to each physician (MD or DO), nurse practitioner, and physician assistant enrolled in Medicare or Medicaid to account for financial losses and non-reimbursable expenses during COVID-19. All organizations have encouraged HHS to help ensure a sufficient physician workforce is available across the country now and throughout this global health crisis.

CMS Administrator Seema Verma seemed to indicate openness to this idea during Tuesday's Coronavirus Task Force briefing, indicating that payments would be provided automatically based on a physician's Medicare revenue. The AAD will provide updates on the status of this potential aid as they become available.

# **COVID-19 dermatology registry**

The Academy is pleased to announce the development of a <u>COVID-19 dermatology</u> <u>registry</u>, which aims to understand dermatologic manifestations of coronavirus. The registry is gathering information from all health care professionals taking care of:

- COVID-19 patients who develop dermatologic manifestations, OR
- dermatology patients with an existing condition who then develop COVID-19

You will be asked for your name, email address, and hospital or private practice, if applicable. Additionally, you'll be asked about the patient's demographic information, details about the patient's new onset dermatologic condition, the patient's past medical history including past dermatologic conditions and treatments, as well as details surrounding the patient's COVID-19 diagnosis and treatment.

## How is the data protected?

Patient identifiers such as name or date of birth will not be collected. All de-identified information will be kept strictly confidential and will only be shared with researchers compiling information. The data is being securely stored in Redcap, hosted by Partners Healthcare (Massachusetts General Hospital), and recently received Massachusetts General Hospital's IRB approval through Harvard.

## Want to participate?

You can access the registry <a href="here">here</a>. The form should take about 5-7 minutes to complete. Please share <a href="this site">this site</a> with your colleagues and encourage them to report any cases of COVID-19 related dermatoses. Note: Patients should not enter their own cases.

### **New Academy PPE guidance**

The Academy has <u>developed guidance</u> to help you preserve protective equipment during the COVID-19 outbreak.

# Your input sought: Coding updates from private payers

Most insurers have expanded access to telemedicine during the COVID-19 pandemic. If you have submitted claims under these policies, please email <a href="mailto:privatepayer@aad.org">privatepayer@aad.org</a> to let us know if your insurer has communicated specific coding requirements. Review

the most recent information the AAD has collected on these policies.

# Update on SBA loan guidance

The SBA shared with Academy staff that applicants will not be able to "double dip" on forgiveness of funds from both the Economic Injury Disaster Loan (EIDL) program and the Payment Protection Program (PPP). Applicants who receive a forgivable advance under EIDL will have the forgiven amount of the advance deducted from the loan forgiveness that the applicant receives under PPP.

If you received an EIDL from **Jan. 31, 2020 through April 3, 2020**, you may apply for a PPP loan subject to the following:

- If the purpose of the EIDL loan was for a purpose other than paying payroll costs, the Applicant may apply for and receive a PPP loan.
- If the purpose of the EIDL loan was to pay payroll costs, PPP loan proceeds must be used to refinance the EIDL loan (not including the amount of any advance made under the EIDL loan, which will not be included in the PPP loan because the advance does not need to be repaid). Additionally, proceeds from any advance up to \$10,000 on the EIDL loan will be deducted from the loan forgiveness amount on the PPP loan.

If you receive an EIDL loan **after April 3, 2020**, then you also may apply for a PPP loan. However, the PPP loan must not be used for the same purpose as the EIDL loan. If the PPP loan is for the same purpose as the EIDL loan, this will be considered an ineligible duplication of benefits.

### State medical liability information

Some states have updated their medical liability rules to protect physicians responding to the pandemic. The AMA and Medical Professional Liability Association have assembled information on these updates.

The AAD will continue to track COVID-19 developments and provide updates on

telehealth, small business relief, clinical guidance, and more via email and at <a href="https://www.aad.org/coronavirus">www.aad.org/coronavirus</a>.

Copyright © 2020 American Academy of Dermatology
Our address is 9500 W Bryn Mawr Avenue, Ste 500, Rosemont, IL 60018, US

If you do not wish to receive future email, click here.

(You can also send your request to **Customer Care** at the street address above.)